Why did the FDA refuse to review Moderna's flu shot?

Agency cites trial shortcomings; company seeks answers

U.S. regulators declined to accept Moderna’s application for an mRNA influenza vaccine because the clinical data did not meet the Food and Drug Administration’s standards for an “adequate and well‑controlled” trial. The agency flagged concerns about the study’s design and the comparator used in Moderna’s trial, saying the submitted evidence was insufficient to support a regulatory review.

Moderna has requested a meeting with the regulator to discuss the decision and to clarify next steps. The company has said it will engage with the FDA to address the agency’s questions. The refusal to accept the application effectively pauses the company’s path toward licensure until a resolution is reached or new data are submitted.

Immediate implications

• The timeline for bringing a new mRNA‑based flu shot to market is delayed, which could affect seasonal vaccination planning if the product had been intended as an alternative to existing vaccines.
• Other developers watching the regulatory path for novel vaccine technologies may reassess trial design and comparator choices to meet FDA expectations.
• The decision has raised industry concern about the review environment for updated or novel vaccines and the potential ripple effects on vaccine research and manufacturing.

What to watch next

Regulators and the manufacturer will likely discuss whether additional trials, reanalysis of existing data, or changes to the comparator arm could address the agency’s criticisms. Until that dialogue produces new data or an agreement, the application will not proceed to formal review, and public‑health planners cannot count on that product being available for upcoming flu seasons.